Tag
Abbott Laboratories revised its financial guidance downward following the unwinding of its relationship with Exact Sciences, sending shares sharply lower. The guidance cut raises fresh concerns about near-term revenue visibility in Abbott's diagnostics segment. Analysts are likely to revise forward estimates pending
Analysts are projecting approximately 30% year-over-year growth for Boston Scientific (BSX) by 2026, driving bullish positioning on the stock. That growth rate, if realized, would significantly outperform the broader medical device peer group and support upward multiple expansion.
Tag
Abbott Laboratories revised its financial guidance downward following the unwinding of its relationship with Exact Sciences, sending shares sharply lower. The guidance cut raises fresh concerns about near-term revenue visibility in Abbott's diagnostics segment. Analysts are likely to revise forward estimates pending
2mo ago · 1 min · Markets
Analysts are projecting approximately 30% year-over-year growth for Boston Scientific (BSX) by 2026, driving bullish positioning on the stock. That growth rate, if realized, would significantly outperform the broader medical device peer group and support upward multiple expansion.
2mo ago · 1 min · Markets
— End of feed —